Here are the DEF 14A proxy statements from VolitionRx Limited (VNRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow VNRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VNRX filings page.
VolitionRx Limited is asking stockholders to vote at its July 17, 2026 annual meeting on director elections, auditor ratification, executive pay, a reduction in authorized shares and a new 2026 Stock Incentive Plan. The board unanimously recommends voting “FOR” all five proposals.
The company recently completed a one‑for‑twenty reverse stock split effective April 28, 2026, and all share figures are retroactively adjusted. As of May 26, 2026, 8,627,191 common shares were outstanding, with directors and executive officers as a group holding 6.9%. Several large investors, including Eight Corporation and Lagoda Investment Management, hold more than 5%. The proxy also details ongoing efforts to remediate previously disclosed material weaknesses in internal control over financial reporting and notes that continuing as a going concern depends on successful commercialization and continued financing.
VolitionRx Limited is asking stockholders to approve two major capital-structure changes. First, the company seeks authorization to issue more than 20% of its outstanding common stock to Lind Global Asset Management XII LLC so that all shares potentially issuable under existing convertible notes and warrants comply with NYSE American Rule 713.
As of the February 9, 2026 record date, VolitionRx had 135,565,326 common shares outstanding. Second, the board is requesting flexible authority to implement a reverse stock split at a ratio between 1‑for‑5 and 1‑for‑20, if it later decides this is in stockholders’ best interests. The reverse split is tied to covenants in the Lind financing and is also described as a tool that could help address the company’s low share price and NYSE American continued listing deficiencies. Both proposals require approval by a majority of voting power present, and the board unanimously recommends voting “FOR” each item.